Skip to main content
Premium Trial:

Request an Annual Quote

BioTheranostics Inks Contract with PPO Prime Health Services

NEW YORK (GenomeWeb News) – Genomic cancer test provider BioTheranostics today announced a contract with preferred provider network Prime Health Services for coverage of BioTheranostics' tests for breast cancer and metastatic disease.

Members of Prime Health now have access to San Diego-based BioTheranostics' molecular-based tests, including the Breast Cancer Index, which quantifies the risk of recurrence of early stage, estrogen receptor-positive breast cancer, and CancerType ID for diagnosing metastatic cancer.

Based in Brentwood, Tenn., Prime Health has more than 700,000 providers and facilities across the US.

BioTheranostics last week announced a contract with PPO Three Rivers Provider Network.